


## Tafetinib

Cat. No.:	HY-116116
CAS No.:	1032265-57-8
Molecular Formula:	C <sub>24</sub> H <sub>29</sub> FN <sub>4</sub> O <sub>2</sub>
Molecular Weight:	424.51
Target:	c-Kit; RET; VEGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

#### Description

Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibits stem cell factor receptor (Kit), vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor-β (PDGFR-β), glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), and Fms-like tyrosine kinase-3 (FLT3) with IC<sub>50</sub> values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation of PDGFR-β and VEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis<sup>[1]</sup>.

### REFERENCES

[1]. Wang D, et al. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor. *Cancer Chemother Pharmacol.* 2012;69(1):173-183.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA